re: Ann: Collaboration with the MRC Hutchison... Two key points were made:
- Phylomers are viable for phenotypic screening (a much more demanding requirement than genotypic screening). Thus an extreme validation of the complexities of the Phylomer shapes and the appropriateness for phenotype diseases, such as cancers.
- If you can discover an active Phylomer shape ... you can build a Phylomer drug. All the Phylomer chemistry work has demonstrated the ability to adapt a discovered Phylomer activity into a drug compound.
This is very good news. It is the crowning moment in demonstrating the efficacy of Phylomers as biotech designed drugs.
Ann: Collaboration with the MRC Hutchison Institu, page-4
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
$1.39 |
Change
0.030(2.21%) |
Mkt cap ! $810.7M | |||
| Open | High | Low | Value | Volume |
| $1.39 | $1.39 | $1.33 | $103.4K | 75.90K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 2600 | $1.37 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.39 | 14999 | 1 |
View Market Depth
| Last trade - 16.10pm 21/07/2025 (20 minute delay) ? |
| PYC (ASX) Chart |